ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response

BACKGROUND: The combination of ISA101, a human papilloma virus (HPV) 16 peptide vaccine, and nivolumab showed a promising response rate of 33% in patients with incurable HPV-16(+) cancer. Here we report long-term clinical outcomes and immune correlates of response. METHODS: Patients with advanced HP...

Descripción completa

Detalles Bibliográficos
Autores principales: de Sousa, Luana Guimaraes, Rajapakshe, Kimal, Rodriguez Canales, Jaime, Chin, Renee L, Feng, Lei, Wang, Qi, Barrese, Tomas Z, Massarelli, Erminia, William, William, Johnson, Faye M, Ferrarotto, Renata, Wistuba, Ignacio, Coarfa, Cristian, Lee, Jack, Wang, Jing, Melief, Cornelis J M, Curran, Michael A, Glisson, Bonnie S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066369/
https://www.ncbi.nlm.nih.gov/pubmed/35193933
http://dx.doi.org/10.1136/jitc-2021-004232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066369/
https://www.ncbi.nlm.nih.gov/pubmed/35193933
http://dx.doi.org/10.1136/jitc-2021-004232

Ejemplares similares